Signaturefd LLC Buys 961 Shares of Eli Lilly and Company $LLY

Posted by Stanley Muller on Oct 27th, 2026

Eli Lilly and Company logo Signaturefd LLC raised its stake in Eli Lilly and Company (NYSE:LLY – Free Report) by 3.7% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 27,035 shares of the company’s stock after acquiring an additional 961 shares during the period. Signaturefd LLC’s holdings in Eli Lilly and Company were worth $31,282,000 at the end of the most recent quarter.

A number of other institutional investors have also recently modified their holdings of the stock. Bank of America Corp DE bought a new position in shares of Eli Lilly and Company in the second quarter worth $13,522,666,000. Jupiter Topco LLC acquired a new position in Eli Lilly and Company in the second quarter valued at about $4,667,180,000. Fifth Third Bancorp lifted its position in Eli Lilly and Company by 321.3% during the first quarter. Fifth Third Bancorp now owns 1,963,490 shares of the company’s stock worth $1,805,959,000 after purchasing an additional 1,497,423 shares during the period. Corient Private Wealth LP bought a new stake in Eli Lilly and Company during the second quarter worth about $764,116,000. Finally, Diamant Asset Management Inc. lifted its position in Eli Lilly and Company by 119,923.8% during the first quarter. Diamant Asset Management Inc. now owns 1,070,612 shares of the company’s stock worth $107,061,000 after purchasing an additional 1,069,720 shares during the period. 82.53% of the stock is currently owned by institutional investors.

Eli Lilly and Company Trading Up 0.5%

LLY opened at $1,279.29 on Tuesday. The company has a market cap of $1.20 trillion, a P/E ratio of 42.93, a PEG ratio of 1.71 and a beta of 0.46. The company has a current ratio of 1.35, a quick ratio of 1.00 and a debt-to-equity ratio of 1.41. The company’s 50 day moving average is $1,187.35 and its 200-day moving average is $1,086.38. Eli Lilly and Company has a 1-year low of $809.63 and a 1-year high of $1,321.21.

Eli Lilly and Company (NYSE:LLY – Get Free Report) last released its quarterly earnings data on Wednesday, August 5th. The company reported $8.38 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.40 by $1.98. The business had revenue of $22.97 billion during the quarter, compared to analysts’ expectations of $20.82 billion. Eli Lilly and Company had a net margin of 33.53% and a return on equity of 97.83%. The firm’s quarterly revenue was up 47.7% compared to the same quarter last year. During the same period in the prior year, the company earned $6.31 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. Equities research analysts predict that Eli Lilly and Company will post 33.22 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, December 10th. Shareholders of record on Friday, November 13th will be paid a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.5%. The ex-dividend date of this dividend is Friday, November 13th. Eli Lilly and Company’s payout ratio is presently 23.22%.

Analyst Ratings Changes

A number of brokerages have issued reports on LLY. Leerink Partners increased their price objective on shares of Eli Lilly and Company from $1,309.00 to $1,316.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 21st. The Goldman Sachs Group restated a “buy” rating and issued a $1,413.00 target price on shares of Eli Lilly and Company in a research report on Tuesday, October 20th. Wells Fargo & Company upped their price target on shares of Eli Lilly and Company from $1,280.00 to $1,330.00 and gave the stock an “overweight” rating in a report on Thursday, August 6th. Cantor Fitzgerald upped their price target on shares of Eli Lilly and Company from $1,410.00 to $1,440.00 and gave the stock an “overweight” rating in a report on Thursday, October 8th. Finally, BMO Capital Markets reiterated an “outperform” rating on shares of Eli Lilly and Company in a research report on Thursday, October 1st. One equities research analyst has rated the stock with a Strong Buy rating, twenty-four have given a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Eli Lilly and Company has an average rating of “Moderate Buy” and a consensus price target of $1,320.25.

View Our Latest Stock Analysis on LLY

Insiders Place Their Bets

In other news, EVP Patrik Jonsson sold 6,500 shares of the stock in a transaction on Monday, August 17th. The stock was sold at an average price of $1,175.10, for a total value of $7,638,150.00. Following the completion of the transaction, the executive vice president directly owned 54,147 shares in the company, valued at approximately $63,628,139.70. This represents a 10.72% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Anat Hakim sold 5,000 shares of the firm’s stock in a transaction on Friday, August 7th. The shares were sold at an average price of $1,190.00, for a total value of $5,950,000.00. Following the sale, the executive vice president directly owned 11,875 shares in the company, valued at approximately $14,131,250. This trade represents a 29.63% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 13,500 shares of company stock valued at $15,958,170. 0.14% of the stock is currently owned by insiders.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

Positive Sentiment: A U.S. judge declined to block Eli Lilly’s advertising for its weight-loss drugs in a case brought by Novo Nordisk. The ruling supports Lilly’s ability to market its obesity treatments and represents a favorable development in the competitive GLP-1 market. US judge won’t block Eli Lilly ads for weight-loss drugs
Positive Sentiment: New clinical data for investigational lung-cancer drug olomorasib showed durable first-line activity in KRAS G12C-mutated non-small-cell lung cancer, strengthening Lilly’s pipeline beyond its obesity and diabetes franchises. New data on Lilly’s investigational treatment olomorasib
Positive Sentiment: Early Phase 1 results for Lilly’s investigational sofe-m plus bevacizumab regimen in ovarian cancer showed high response and disease-control rates without major new safety signals. Although preliminary, the data add potential long-term value to the oncology pipeline. Lilly reports strong Phase 1 ovarian cancer data
Positive Sentiment: The board declared a quarterly dividend of $1.73 per share, payable December 10 to shareholders of record November 13. The announcement provides a modest signal of financial confidence, though the dividend is not likely to be the primary stock catalyst. Lilly declares fourth-quarter 2026 dividend
Neutral Sentiment: Analysts have high expectations for the October 29 earnings report, with investors focused on demand for weight-loss drugs, prescription trends, manufacturing capacity and updated full-year guidance. A strong report could extend the rally, while any miss could prompt volatility. Wall Street has high expectations for Eli Lilly
Negative Sentiment: Competition from Novo Nordisk and broader pricing, patent and market-access pressures remain risks. Analysts also caution that revenue could temporarily soften even as patient numbers grow, while Lilly’s elevated valuation leaves the stock sensitive to weaker-than-expected guidance. Why revenue could dip even as patients grow

About Eli Lilly and Company

(Free Report)

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its major therapeutic areas include diabetes and obesity, oncology, immunology, neuroscience and cardiovascular health.

The company’s portfolio includes Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, Humalog insulin, Taltz for inflammatory diseases, Verzenio for certain breast cancers and Kisunla for early symptomatic Alzheimer’s disease.